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an increasing funding shortfall. Novel strategies include commu-
nity models of care, for testing, adherence support and delivery of
ART.
AIDS is far from over as challenges ahead dwarf the impressive
achievements of ART scale up to date. Yet treatment as prevention
is already showing early signs of success...
http://dx.doi.org/10.1016/j.ijid.2014.03.479
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Randomized, placebo-controlled trial on safety
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Background: Pregnant women and young infants are at
increased risk for severe inﬂuenza-illness. Inﬂuenza vaccination
duringpregnancymay confer indirect protection against inﬂuenza-
illness to infants <6 months of age, for whom there is no licensed
inﬂuenza vaccine. A co-primary objective of our study was to eval-
uate the efﬁcacy of trivalent inactivated inﬂuenza vaccine (IIV3)
when given during pregnancy against PCR-conﬁrmed inﬂuenza-
illness (PCI) in their infants up until 6 months of age.
Methods & Materials: We conducted a double-blind, random-
ized, placebo-controlled trial in Soweto, South Africa during the
2011 and 2012 inﬂuenza seasons. 2116 HIV-uninfected women
were randomized to receive IIV3 or placebo intramuscularly
between 20-36 weeks gestation. Infants were screened weekly
for inﬂuenza-like-illness (ILI) after birth. When ILI was suspected
nasopharyngeal aspirates were collected for inﬂuenza A and B
testing by real-time PCR. Inﬂuenza A viruses were subtyped for
A/H1N1pdm09 and H3N2 and inﬂuenza B isolates were tested for
Yamagata and Victoria lineages.
Results:Pregnancyoutcomeswere similar between the IIV3and
placebo-group, including 8 miscarriages and 22 stillbirths. 2048
babies were born alive, 1025 and 1023 to mothers who received
IIV3 andplacebo, respectively. The rates of pretermdeliveries (10%)
and low birth weight (12.4%) were also similar between the study
groups. 706 and 698 illness visits were completed in infants of
mothers who received IIV3 and placebo, respectively; of which
665 (64.9%) and 656 (64.1%) illness episodes fulﬁlled ILI crite-
ria. In infants born to IIV3-recipients, 19 PCI cases were detected
compared to 37 in infants born to placebo-recipients, resulting
in vaccine efﬁcacy of 48.8% (95%CI: 11.5% to 70.3%) against PCI
in infants. Excluding the non-vaccine inﬂuenza B/Yamagata cases
from the analysis vaccine efﬁcacy (VE) did not change (VE: 48.1%;
95%CI: -0.9% to 73.3%). In twelve (21.4%) of the 56 PCI cases among
infants (including 11 whose mothers received placebo), PCI was
also identiﬁed concurrently in the mother.
Conclusion: Vaccination of African pregnant women with IIV3
was safe and reduced PCI in their infants by 49% up until 6 months
of age. Immunization of pregnant women with IIV3 is warranted
for the protection of their young infants.
http://dx.doi.org/10.1016/j.ijid.2014.03.480
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Background: Acute respiratory infections (ARIs) are a major
cause ofmorbidity andmortality among childrenworldwide. How-
ever, information about viral etiologies ofARIs fromdeveloping and
tropical countries is limited. Understanding the etiologies of ARIs
in hospitalized children is essential for improving prevention, diag-
nosis and treatment in these settings. This study was conducted to
describe the clinical and epidemiologic characteristics of viral ARIs
in hospitalized children in Vietnam.
Methods & Materials: From April 2010 to May 2011, clinical
data and nasopharyngeal (NP) samples were collected from chil-
dren with ARIs admitted to Children’s Hospital 2 at Ho Chi Minh
City, Vietnam. Four multiplex PCR assays were performed to detect
13 respiratory viruses in NP samples.
Results: A total of 1,082 were enrolled. At least one pathogen
wasdetected in 64%of caseswith 9.1%were co-infections. Themost
frequent pathogens were rhinovirus (RV) (30%), respiratory syncy-
tial virus (RSV) (23.8%), human bocavirus (HBoV) (7.2%) followed
by parainﬂuenzae virus (PIV) type 3 (5.3%), PIV type 1 (3.3%), and
inﬂuenzaA (FluA) (3.2%). RV infectionoccurredall year round,while
RSV epidemic occurred mainly in the rainy season. FluA infections
peaked in both seasonswith seasonal H3N2 in the rainy season and
pandemic H1N1 2009 in the dry season. Other viruses were pre-
dominant in thedry season.RV infectionsoccurred inall agegroups.
RSV, PIV3, PIV1 and HBoV, FluA caused infections predominantly
in children<6 months, 6 – 12 months, 12 – 24 months, and>24
months, respectively. Signiﬁcant associations were found between
PIV1 with croup (p<0.005) and RSV with bronchiolitis (p <0.005).
HBoVandRV infectionswere associatedwithhypoxia (p <0.05) and
RSV infectionswith lower chest indrawing (p<0.05). RSV subgroup
A had severity score higher than subgroup B (p<0.05). Pandemic
H1N1 2009 and co-infections did not lead to more severe symp-
toms.
Conclusion: A high incidence of virus-associated ARIs, in which
RV, RSV and HBoV were the leading causes, was found among hos-
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pitalized children in Vietnam. RV, RSV, and HBoV may increase the
severity of ARIs in children.
http://dx.doi.org/10.1016/j.ijid.2014.03.481
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Background: Polio eradication is a global health priority and
Pakistan is among last three endemic countries. Supplementary
immunization activities (SIAs) with oral poliovirus vaccines are
usually separated by four week intervals; however, shorter inter-
vals have been used in security compromised areas and for rapid
outbreak response. We assessed immunogenicity of monovalent
type 1 oral poliovirus vaccines (mOPV1) administered at shorter
than usual intervals in a cohort of infants in Karachi, Pakistan.
Methods & Materials: A randomized controlled trial was con-
ducted to compare immunogenicity of two doses of mOPV1 given
at 7 or 14 day-intervals with standard 30 day interval. In addition,
bivalentOPV1&3 (bOPV)was administered at 30-day interval. Birth
trivalent OPV and two study OPV doses were administered and
blood samples obtained at birth, six weeks of age and one month
after the last OPV dose. Bloodwas tested for poliovirus neutralizing
antibodies.
Results: A total of 1009 newborns were enrolled, and 829
(82%) met eligibility criteria for randomization at 6 weeks; 554
(55%) were included in the per protocol analysis. Seroprevalence of
poliovirus neutralizing antibodies for poliovirus type 1 after three
doses of OPV was>95% for all arms. Among those who did not
seroconvert after birth dose, no signiﬁcant differences in serocon-
version to poliovirus type 1 after two study OPV doses were found
between study arms (75.0% [CI95%=65-83%] for mOPV1 given at
7 day interval, 75.0% [CI95%=65-83%] for mOPV1 at 14 day inter-
val, 78.1% [CI95%=69-86%] for mOPV1 at 30 day interval and 72.6%
[CI95%=63-81%] for bOPV at 30 day interval).
Conclusion: We found no differences in immunogenicity of
mOPV1 administered in shorter than standard intervals. These
results provide the scientiﬁc justiﬁcation for the expanded use of
the short-interval strategy to rapidly increase population immu-
nity, to control outbreaks, prevent importations, and in areas of
conﬂict where limited window of access can be created.
Funding: The World Health Organization
http://dx.doi.org/10.1016/j.ijid.2014.03.482
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gene therapy for the treatment of chronic
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Background: About 350 million people are chronically infected
with Hepatitis B Virus (HBV) and only a fraction will clear the
virus during their life-time. Current therapeutic options are unsat-
isfying, and life-long appliance of nucleoside-analogs can lead to
side effects and selection of resistant mutants. A new therapeu-
tic approach is to target viral mRNA transcripts for degradation
by the RNA induced silencing complex (RISC). This method holds
immense potency since theoretically an effective and long-term
suppression of viral transcripts can be achieved by a single dose of a
vector encoding for a short-hairpin RNA (shRNA). fter initial enthu-
siasm, reports of severe side effects in animal studies hampered
RNAi-based gene therapies entering the clinics. Several causative
mechanisms have been proposed: (1) Oversaturation of endoge-
nous factors, particular of Argonaute 2, leading to breakdown of
microRNA processing; (2) off-target effects caused by activity of
the passenger strand; and (3) artiﬁcial feeding of shRNAs into the
microRNA pathway downstream of drosha.
Methods & Materials: We designed a range of recombinant
Adeno-associated-virus (AAV) vectors expressing factors to specif-
ically address each of the proposedmechanisms: (1) Co-expression
of the shRNAwithArgonaute2; (2) co-expressionof the shRNAwith
a decoy to neutralize the passenger strand; and (3) expression of
the same siRNA-sequence from a microRNA backbone using a liver
speciﬁc polymerase III promoter. Vectors were injected i.v. in HBV-
transgenicmice and compared for efﬁcacy of HBV-suppression and
signs of toxicity.
Results: While the conventional approach of a polymerase III
promoter driven shRNA led to reductions of HBV-parameters of up
to 97% but was accompanied by elevated ALT levels and loss of
body-mass, co-expression of Argonaute 2 with the shRNA reduced
signs of toxicity with similar efﬁcacy of HBV-suppression. More
noteworthy, co-expression of the passenger strand decoy with the
shRNA not only abrogated toxicity, but also signiﬁcantly enhanced
HBV-suppression with long-term reductions of 99%. Liver speciﬁc
expression of the microRNA mimic showed ameliorated toxicity
but was less efﬁcient in suppressing HBV.
Conclusion: Understanding the mechanisms of RNAi-related
toxicity and the rational design of new expression vectors could
lead to the development of safe and efﬁcient RNAi-based thera-
peutics for chronic Hepatitis B.
http://dx.doi.org/10.1016/j.ijid.2014.03.483
